Good evening. Here's what's moving in the world of medical cannabis today.
NORML calls for renewed support in fight for cannabis justice
The US advocacy organisation NORML has issued a public appeal for continued support, arguing that the fight for "justice, equity, and freedom" in cannabis policy is far from finished. In a post published on 25 May 2026, the group stressed that the campaign is not about protecting commercial interests in the legal market, but about completing the broader reform agenda.
NORML, one of the longest-standing cannabis law reform groups in the United States, has been active since the 1970s. The appeal comes amid ongoing uncertainty around federal rescheduling and the pace of state-level medical programme expansions.
UK medical cannabis sector awaits further regulatory clarity
No new UK-specific stories appeared in today's headlines, but the domestic medical cannabis sector continues to operate under the framework established by the 2018 reclassification. Clinics registered with the Care Quality Commission (CQC) remain the primary route for patient access, whilst NHS prescribing remains extremely limited.
Patient advocacy groups have repeatedly called for clearer guidance from the National Institute for Health and Care Excellence (NICE) and for the Home Office to address barriers faced by clinicians. The lack of new regulatory updates today underscores the slow pace of policy movement in the UK.
European cannabis policy developments remain quiet
No major European Union or member-state policy announcements appeared in today's feed. Germany's medical cannabis programme, which expanded significantly following the 2024 non-classification of cannabis as a narcotic, continues to operate under its current framework. The European Parliament has not issued any new statements on cannabis policy today.
International research landscape shows no new publications today
No new peer-reviewed studies or clinical trial announcements featured in today's headlines. The absence of fresh research updates is not unusual, as major medical journals and research conferences operate on irregular publication schedules. The cannabis research community continues to produce work on cannabinoids for chronic pain, epilepsy, and mental health conditions, though no new data was released today.
